Akari Therapeutics Plc

Akari Therapeutics Plc is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Akari Therapeutics Plc is not a good value stock. Akari Therapeutics Plc has good growth characteristics. Akari Therapeutics Plc is not very popular among insiders. Akari Therapeutics Plc is a mediocre stock to choose.
Log in to see more information.
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the developme...
AKTX Fundamental Data by TradingView

News

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com
Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

Ticker Report StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the...\n more…

Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Ticker Report StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a report released on Friday morning. The firm issued a sell rating on the biopharmaceutical company's...\n more…

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com
Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

Zolmax StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a report released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company's...\n more…

Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Ticker Report Analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Get Free Report) in a report released on Thursday. The firm set a "sell" rating on the biopharmaceutical...\n more…

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Globe Newswire Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology...\n more…

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Globe Newswire Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophyBOSTON and LONDON, Aug. 19, 2024 (GLOBE...\n more…